Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
- Conditions
- Advanced Solid Tumour
- Interventions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 210
- Registration Number
- NCT06783647
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Xiangyang Central Hospital, Xiangyang, Hubei, China
🇨🇳Mianyang Central Hospital, Mianyang, Sichuan, China
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Conditions
- Non Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 172
- Registration Number
- NCT06772623
- Locations
- 🇺🇸
Providence - St. Jude Medical Center /ID# 271414, Fullerton, California, United States
🇺🇸FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450, Oxnard, California, United States
🇺🇸Mid Florida Hematology And Oncology Center /ID# 273777, Orange City, Florida, United States
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
- Conditions
- Leptomeningeal Metastasis
- Interventions
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Guangzhou Medical University
- Target Recruit Count
- 36
- Registration Number
- NCT06762080
- Locations
- 🇨🇳
The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, Guangdong, China
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
- Conditions
- Advanced NSCLCAdvanced Endometrial Cancer
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 282
- Registration Number
- NCT06758557
- Locations
- 🇨🇳
Affiliated Hospital of Hebei University / School of Clinical Medicine, Baoding, Hebei, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, China
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 464
- Registration Number
- NCT06754644
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 318
- Registration Number
- NCT06745882
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
- Conditions
- Advanced Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 402
- Registration Number
- NCT06738251
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT06731907
- Locations
- 🇺🇸
MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States
🇬🇷European Interbalkan Medical Center-Oncology Department ( Site 0205), Thessaloniki, Greece
🇮🇱Rambam Health Care Campus ( Site 0076), Haifa, Israel
A Study of SKB264 in Combination with Pembrolizumab Versus Chemotherapy in Combination with Pembrolizumab As First-Line Treatment for PD-L1 Negative Patients with Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 432
- Registration Number
- NCT06711900
- Locations
- 🇨🇳
Shanghai Oriental Hospital, Shanghai, China
Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 982
- Registration Number
- NCT06712316
- Locations
- 🇺🇸
Alaska Oncology and Hematology, LLC, Anchorage, Alaska, United States
🇺🇸Clermont Oncology Center, Clermont, Florida, United States
🇺🇸Physicians Clinic of Iowa, Cedar Rapids, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.